| Date | Title | | | May.24.13 | Actavis, Inc. to Present at the Sanford C. Bernstein Twenty-Ninth Annual Strategic Decisions Conference 2013| PARSIPPANY, N.J., May 24, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Actavis' President and Chief Executive Officer, will provide an overview and update of the Company's business at the Sanford C. Bernstein Twenty-Ninth Annual Strategic Decisions Conference on Thursday, May 30, 2013 at 4:00 PM Eastern Time at the Waldorf Astoria Hotel in New York, New York. The presentation will be webcast live and can be accessed... |
|  | | May.24.13 | Actavis Confirms Appeals Court Issues Injunction Related to Generic Pulmicort RESPULES® Distribution| PARSIPPANY, N.J., May 24, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today confirmed that the United States Court of Appeals for the Federal Circuit has granted a motion by AstraZeneca to enjoin Actavis from further distribution of its generic version of AstraZeneca's Pulmicort RESPULES® (budesonide inhalation suspension) 0.25, 0.5 mg products, pending resolution of AstraZeneca's appeal before the Court.
Actavis launched its generic product on April 1, 2013, following a ruling from the U... |
| | | May.20.13 | Actavis to Acquire Warner Chilcott to Create Premier $11 Billion Revenue Global Specialty Pharmaceutical Company| - Top 3 U.S. ~$3.0 Billion Revenue Specialty Brand Business -
- Expands Portfolio and Pipeline in Core Areas of Women's Health and Urology -
- Adds Gastroenterology and Dermatology Franchises and Infrastructure -
- Stronger Commercial Presence to Support Expanded Brand Pipeline -
- Immediately Accretive With Opportunities for Substantial Operational Synergies and Tax Savings -
- Combination Expected to Generate Strong EBITDA and Cash from Operations -
- All Stock Transaction Fu... |
| | | May.14.13 | Announcement Under Irish Takeover Rules Relevant Securities in Issue| PARSIPPANY, N.J., May 14, 2013 /PRNewswire/ -- In accordance with Rule 2.10 of the Irish Takeover Rules, Actavis, Inc. (NYSE: ACT), a global specialty pharmaceutical leader, (the "Company") confirms that, as at the latest practicable date prior to the making of this announcement, the Company's issued share capital consisted of 133,305,212 ordinary shares, excluding treasury shares, par value US$0.033 per share (the "Ordinary Shares"). The International Securities Identification Number for these ... |
| |
|
Country websites
